PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

ustekinumab Side Effects

The reactions most often reported to the FDA for ustekinumab (also sold as Stelara), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

98,899
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2009 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of ustekinumab come from 98,899 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 98,899 reports to the FDA Adverse Event Reporting System (FAERS) for ustekinumab (Stelara): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

98,899

Reports Mentioning Death

5,465

5.5% of reports — not proof the medicine caused the death

Hospitalizations

21,428

21.7% of reports

Top Indication

Psoriasis

Most Reported Adverse Reactions

FATIGUE
6,589
PSORIASIS
6,433
PAIN
6,033
ARTHRALGIA
5,628
CROHN^S DISEASE
5,563
RASH
5,437
HEADACHE
5,129
CONDITION AGGRAVATED
5,057
INFUSION RELATED REACTION
4,945
RHEUMATOID ARTHRITIS
4,644
JOINT SWELLING
4,567
HYPERSENSITIVITY
4,467
DIARRHOEA
4,464
SYNOVITIS
4,423
ALOPECIA
4,408
HEPATIC ENZYME INCREASED
4,304

Who Reports Side Effects

Gender Distribution

Female 51,237 (60%)
Male 34,661 (40%)
Unknown 192

Age Distribution

0-17 3,844 (7%)
18-44 21,364 (39%)
45-64 21,106 (38%)
65-74 6,358 (11%)
75+ 2,679 (5%)

Reporting Trend by Year

2009 2025

Reactions in Death Reports

Top reactions reported in 5,465 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
TYPE 2 DIABETES MELLITUS 1,672
WOUND 1,660
SYSTEMIC LUPUS ERYTHEMATOSUS 1,649
GLOSSODYNIA 1,642
HAND DEFORMITY 1,629
JOINT SWELLING 1,626
INFUSION RELATED REACTION 1,624
SYNOVITIS 1,618
GENERAL PHYSICAL HEALTH DETERIORATION 1,616
RASH 1,591
RHEUMATOID ARTHRITIS 1,591
FATIGUE 1,585
HEPATIC ENZYME INCREASED 1,585
HYPOAESTHESIA 1,583
FIBROMYALGIA 1,573
HYPERTENSION 1,565
HELICOBACTER INFECTION 1,551
SWELLING 1,550
PSORIATIC ARTHROPATHY 1,549
DUODENAL ULCER PERFORATION 1,532

Reactions in Hospitalization Reports

Top reactions in 21,428 reports where hospitalization was an outcome.

Reaction Reports
FATIGUE 2,702
PAIN 2,508
RHEUMATOID ARTHRITIS 2,459
ARTHRALGIA 2,412
RASH 2,403
INFUSION RELATED REACTION 2,313
SYNOVITIS 2,297
JOINT SWELLING 2,251
PNEUMONIA 2,223
HEADACHE 2,217
GENERAL PHYSICAL HEALTH DETERIORATION 2,212
HEPATIC ENZYME INCREASED 2,196
DIARRHOEA 2,194
CONDITION AGGRAVATED 2,192
HYPERSENSITIVITY 2,144
CROHN^S DISEASE 2,132
VOMITING 2,118
SYSTEMIC LUPUS ERYTHEMATOSUS 2,108

Compare ustekinumab vs adapalene →

What the FAERS Data Reveals About ustekinumab Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 98,899 voluntary reports linked to ustekinumab and its brand equivalents (Stelara), spanning 2009 through 2025. Of those, 5,465 (5.5%) listed death as an outcome and 21,428 (21.7%) involved hospitalization. The most common indication reported alongside adverse events was Psoriasis.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 60% were female and 40% male; age distribution skews toward 18-44, with 21,364 reports in that bracket. The single most reported reaction is fatigue with 6,589 submissions, followed by psoriasis and pain.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.